Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, is pleased to announce that its Midkine program was presented on 3 December 2022 at the European Society of Medical Oncology Asia conference in Singapore. The presentation reported that the lead oligonucleotide program showed >90% efficacy in human cancer cells (at the mRNA level), reduced functional Midkine and is ready for efficacy testing as a novel anticancer medicine.

The poster and abstract were embargoed until the presentation at the conference:

https://www.esmo.org/meeting-calendar/esmo-asia-congress-2022

https://www.londonstockexchange.com/news-article/ROQ/presentation-of-midkine-oligonucleotide-program/15743584

​